CYP2D6 and Hepatic failure: Similar findings had been reported in other studies,[6] such as NCT01465802, NCT00728468, and NCT00548093.[11] A phase II, open-label trial of dacomitinib (PF-00299804), as a single oral agent in selected patients with adenocarcinoma of the lung (ClinicalTrials.gov identifier: NCT00818441),[22] reported a case death, who developed hepatic failure likely due to an interaction of dacomitinib and mirtazapine, which metabolized by CYP2D6.